Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yup and what is it now?
Obviously a typo.
The correct number is 405,073,773
I pointed it out to Dianne.
Have a nice weekend all!
As long as the company's cash flow is adequate to meet its bills, it can continue operating indefinitely, regardless of what its shareholder equity is. Inversely, if cash flow is inadequate, it will wind up in bankruptcy court even if on paper it has high shareholder equity. Shareholder equity is an accounting measure with at times a limited relationship with reality.
excuse me?
Well that explains all the timing:
FDA meeting regarding ELI-200 on November 17th.
FWIW:
Just two quarters ago they announced on a Friday in the AM and in June they announced Friday at 2pm.
My pleasure. The longer than usual gap between the financials release and CC is interesting.
Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on Wednesday, November 19, 2014
….Second Quarter Financials for Fiscal Year 2015 Are Scheduled To Be Filed on Friday, November 14, 2014
Damn right.
If ELTP was followed by multiple credible independent analysts, had published independent valuations models, had major institutional investors, was on the NASDAQ, etc....it wouldn't be .30/share and the investment opportunity would be long gone.
Those with the vision to buy well ahead of these occurrences are the ones that will benefit greatly, just as we did when we bought in .03's, .04's and .05's.
I'm number 1 to me and I haven't had any losses on ELTP.
...We believe this is what we need to do, and then the FDA will tell you if you’ve gone to their standards or to their base or not. So we will have a lot of feedback hopefully after October from the FDA.
What "negative surprise" are you expecting?
What bad news do you expect?
"In large part, companies obtain the shareholder constituency that they seek and deserve. If they focus their thinking and communications on short-term results or short-term stock market consequences, they will, in large part, attract shareholders who focus on the same factors."
Warren Buffett
We have plenty of data. Whether in the eyes of the FDA we have sufficient data to avoid an additional trial for efficacy remains to be seen. In addition the FDA will want a pediatric study. The question there is will the FDA allow Elite to conduct that study after filing their NDA or before.
If after any approval can be contingent on satisfactory pediatric study results. That would be ideal as it would not slow us down. If the FDA requires an efficacy study that could delay filing of an NDA for a good 6 months.
We are all waiting to hear from Nasrat if/when he has or will meet with the FDA and what the FDA had to say about any additional trials.
What does POS mean?
Do you truly believe that JL?
If so, why?
Have a great weekend either way.
Yet price went up.
Yes, perhaps so...still would be pretty damn good.
IB
I don't have PM w/ free account...
but, it's quite possible.
Indeed.
But $210,000,000 is quite achievable.
I'm only counting US, not Canada or Europe
I'm only assuming 30% of Opioid market to be ARTs/ADT's
I'm only assuming 10% market share of the ART/ADT market in the US.
...and even with all of that we have a 50 fold increase in sales.
What would that do to the share price?
So for me I'll use the $7 billion US market figure.
Assuming say 30% of that market is Abuse Deterrent three years from now based on a phasing in of ART/ADT rather than the FDA hitting the switch and mandating across the board.
So now it's $2.1 billion market opportunity three years from now.
Now let's assume Elite gets a 10% share of that market.
That's $210,000,000 in sales.
That is oh, about 50 times their current sales figure that supports a price of .32/share.
So, this is still looking mighty good to me!
The global market for narcotic and non-narcotic pain treatments was $22.4 billion in 2009, according to health research firm IMS Health Inc.
See, thats my point. 22.4 billion is narcotic and non-narcotic combined.
The abuse resistant opportunity lies in the narcotic/opioid market only.
From a brief stroll across the internet I see:
In 2012, the U.S. opioid market was $8.5 billion, and the worldwide market was $11.7 billion
http://www.signaturerx.com/view.cfm/7/Corporate-Overview
Global opioid market is $12 billion,
http://phosphagenics.com/site/DefaultSite/filesystem/documents/2014%20Apr%2003%20Phosphagenics%20Investor%20Presentation%20Webcast.pdf (Slide 4)
...of the $14.8 billion global opioid market
http://www.nektar.com/pdf/20130305.pdf
So...11.7 to 14.8 billion works for me.
Some may be confusing the total market for "Pain" as opposed to "opioids"
According to IMS Health, the 2013 U.S. market for opioid analgesics was $8.3 billion. Of this, extended release opioids accounted for approximately $4.3 billion. The market leader, controlled release oxycodone (primarily OxyContin®) had annual sales of $2.5 billion in 2013 (IMS Health).
So ...$20 billion "worldwide" seems plausible to me.
I certainly will do that ...
But since they work out of an over 30,000 square feet of Good Manufacturing Practice (“GMP”) and DEA registered facility for research, development and manufacturing..... I won't ever have to.
The now nearly 40 employees, including the three doctors recently hired are working hard there.
It's two brick buildings and the truck indeed moves.
Thanks, that was a very informative post relevant to ELTP.
lmgtfy.com is very helpful DD tool.
Keep up with the excellent DD and thanks for sharing!
You don't say? Why so cryptic?
Did Elite report earnings today?
I don't think that's due for another couple of weeks.
I wouldn't think so at all. In the grand scheme it's an investment that could pay itself several times over.
That I would agree with. Although it seems they intend to go it alone that doesn't preclude the possibility that this is all posturing.
From Dr LePree's LinkedIn profile:
Design, implement and oversee in-vitro challenge tests for abuse resistant narcotic formulations.
So all you are asserting is that there is no "imminent" (like in the next 24 hours) buyout.....
OK, no surprise there.
But a buyout is certainly possible in the next few months.
Serious question.
How would we know that hasn't happened? Would Elite have to disclose that another company has requested such a list?
227,000 shares on the bid...
Excuse me?
@ Steges...I've been about that long as well.
Suffered through the Bernie Berk era...